|  |
| --- |
| **REQUEST FORM**  **Proposed (invented) product name(s)** |

This form should be filled in by the marketing authorisation holder and submitted to [godkendelse@dkma.dk](mailto:godkendelse@dkma.dk).

|  |  |
| --- | --- |
| **Details of the request**  **(to be filled in by the Marketing Authorisation Holder )** | |
| **Date** |  |
| **Name of the marketing authorisation holder** |  |
| **Contact details**  **Telephone**  **Email** |  |
| **Marketing authorisation number(s)** |  |
| **Strength(s) and pharmaceutical form** |  |
| **Procedure number** |  |
| **Currently approved name** |  |
| **Proposed (invented) name(s) in the order of priority (no more than two proposals)** | 1.  2. |
| **Additional information** |  |

|  |  |
| --- | --- |
| **Acceptability Review**  **(to be filled in by the Danish Medicines Agency)** | |
| **Review / acceptability** | Review:  **Acceptability**:  Is the proposed product name(s) acceptable?  Yes\*  No  \* *the decision is valid for 30 days as per the CMDv BPG for variations not requiring assessment.*  Additional comments from DK:    Note that DK’s acceptability of the name(s) will be followed by a national approval letter after finalisation of the VNRA. The letter will contain information related to the national implementation of the change of a medicinal product name. Please refer to DKMA’s national “[Guideline on variations to marketing authorisations for medicinal products for animal use](https://laegemiddelstyrelsen.dk/en/licensing/licensing-of-medicines/variations/~/media/B03285276CB0410491159A57D5682788.ashx)”. |
| **CaseID** | Please state the Danish CaseID in the UPD database upon submission of the variation. |
| **Member State** | DK |
| **Date** |  |
| **Contact/regulatory project leader responsible for review** |  |
| **Telephone** | +45 |
| **E-mail** | @dkma.dk |
|  |  |
|  |  |
|  |  |